• Explore /
  • Poster
  • / Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up.

Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up.

Abstract Video & Slides Poster

Authors

null

Jeff Porter Sharman

Willamette Valley Cancer Institute and US Oncology Research Center, Eugene, OR

Jeff Porter Sharman , Miklos Egyed , Wojciech Jurczak , Alan Skarbnik , John M. Pagel , Manali K. Kamdar , Talha Munir , Gillian Corbett , Laura Maria Fogliatto , Yair Herishanu , Versha Banerji , Steve E. Coutre , Patricia Walker , Karin Karlsson , Paolo Ghia , Ann Janssens , William G. Wierda , Priti Patel , Min Hui Wang , John C. Byrd

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 7509)

DOI

10.1200/JCO.2021.39.15_suppl.7509

Abstract #

7509

Abstract Disclosures

Similar Posters

First Author: Jeff Porter Sharman

First Author: Wojciech Jurczak

Poster

2021 ASCO Annual Meeting

Capmatinib in <em>MET</em> exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.

Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.

First Author: Juergen Wolf

First Author: Othman Al-Sawaf